Cargando…
Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer()
Tissue factor pathway inhibitor-2 (TFPI-2) is a potent inhibitor of plasmin, a protease which is involved in tumour progression by activating (MMPs). This therefore makes TFPI-2 a potential inhibitor of invasiveness and the development of metastases. In this study, low levels of TFPI-2 expression we...
Autores principales: | Lavergne, Marion, Jourdan, Marie-Lise, Blechet, Claire, Guyetant, Serge, Pape, Alain Le, Heuze-Vourc’h, Nathalie, Courty, Yves, Lerondel, Stephanie, Sobilo, Julien, Iochmann, Sophie, Reverdiau, Pascale |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722576/ https://www.ncbi.nlm.nih.gov/pubmed/23905012 http://dx.doi.org/10.1016/j.fob.2013.06.004 |
Ejemplares similares
-
TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions
por: Gaud, Guillaume, et al.
Publicado: (2011) -
High kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumour proliferation and poor prognosis
por: Nathalie, Heuzé-Vourc’h, et al.
Publicado: (2009) -
Human kallikrein-related peptidase 12 stimulates endothelial cell migration by remodeling the fibronectin matrix
por: Kryza, T., et al.
Publicado: (2018) -
Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer
por: Rollin, J, et al.
Publicado: (2005) -
Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States
por: Ferreira, Marion, et al.
Publicado: (2021)